## Iris Dotan

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6226529/publications.pdf

Version: 2024-02-01

109321 91884 5,549 124 35 69 citations h-index g-index papers 127 127 127 5896 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Randomized Controlled Trial of Cognitive-Behavioral and Mindfulness-Based Stress Reduction on the Quality of Life of Patients With Crohn Disease. Inflammatory Bowel Diseases, 2022, 28, 393-408.	1.9	21
2	Perianal Crohn's Disease Is Associated With Poor Disease Outcome: A Nationwide Study From the epillRN Cohort. Clinical Gastroenterology and Hepatology, 2022, 20, e484-e495.	4.4	15
3	Exploring Popular Social Media Networks for Patients With Inflammatory Bowel Diseases. Journal of Clinical Gastroenterology, 2022, 56, e203-e208.	2.2	7
4	Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN. Gut, 2022, 71, 287-295.	12.1	12
5	Endoscopic Assessment of the Pouch: An Essential Step Forward. Journal of Crohn's and Colitis, 2022, 16, 1-1.	1.3	O
6	Long-term Antibiotic Treatment in Pouchitis—Patterns of Use and Safety. Inflammatory Bowel Diseases, 2022, 28, 1027-1033.	1.9	6
7	Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFî±. Gastroenterology, 2022, 162, 454-467.	1.3	68
8	The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 49-59.	8.1	76
9	Colectomy Rates did not Decrease in Paediatric- and Adult-Onset Ulcerative Colitis During the Biologics Era: A Nationwide Study From the epi-IIRN. Journal of Crohn's and Colitis, 2022, 16, 796-803.	1.3	21
10	Improved Outcomes of Paediatric and Adult Crohn's Disease and Association With Emerging Use of Biologics–A Nationwide Study From the Epi-IIRN. Journal of Crohn's and Colitis, 2022, 16, 778-785.	1.3	16
11	Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. The Lancet Gastroenterology and Hepatology, 2022, 7, 17-27.	8.1	44
12	Fecal Calprotectin Is Increased in Pouchitis and Progressively Increases With More Severe Endoscopic andÂHistologic Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 1839-1846.e2.	4.4	7
13	Risk of Cancer in Paediatric onset Inflammatory Bowel Diseases: A Nation-wide Study From the epi-IIRN. Journal of Crohn's and Colitis, 2022, 16, 786-795.	1.3	13
14	Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an openâ€label, longâ€term extension study with up to 7.0Âyears of treatment. Alimentary Pharmacology and Therapeutics, 2022, 55, 464-478.	3.7	73
15	Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482110686.	3.2	5
16	The risk of advanced neoplasia after polypectomy of one to two non-advanced adenomas less than 5Âmm in size vs. normal colonoscopy. Digestive and Liver Disease, 2022, , .	0.9	0
17	Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel. Digestive and Liver Disease, 2022, 54, 192-197.	0.9	12
18	COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated With Disease Exacerbation. Clinical Gastroenterology and Hepatology, 2022, 20, e1263-e1282.	4.4	53

#	Article	IF	CITATIONS
19	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clinical Gastroenterology and Hepatology, 2022, 20, 2619-2627.e1.	4.4	9
20	Reply to Antibiotic Use Patterns in the Management of Chronic Pouchitis. Inflammatory Bowel Diseases, 2022, , .	1.9	1
21	COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience. Vaccines, 2022, 10, 376.	4.4	1
22	Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. The Lancet Gastroenterology and Hepatology, 2022, 7, 390-391.	8.1	6
23	Meta-Analysis of IBD Gut Samples Gene Expression Identifies Specific Markers of Ileal and Colonic Diseases. Inflammatory Bowel Diseases, 2022, 28, 775-782.	1.9	4
24	Advanced technology for assessment of endoscopic and histological activity in ulcerative colitis: a systematic review and meta-analysis. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210925.	3.2	6
25	Realâ€world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel disease: <scp>ERELATE</scp> Study. Alimentary Pharmacology and Therapeutics, 2022, 56, 463-476.	3.7	12
26	<i>Escherichia coli</i> Strains from Patients with Inflammatory Bowel Diseases have Disease-specific Genomic Adaptations. Journal of Crohn's and Colitis, 2022, 16, 1584-1597.	1.3	5
27	Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes. Clinical Gastroenterology and Hepatology, 2021, 19, 2444-2446.e2.	4.4	8
28	Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable. Clinical Gastroenterology and Hepatology, 2021, 19, 1564-1572.e5.	4.4	11
29	Commensal fungi and their cellâ€wall βâ€glucans direct differential responses in human intestinal epithelial cells. European Journal of Immunology, 2021, 51, 864-878.	2.9	8
30	Doseâ€dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pyloriâ€positive patients. United European Gastroenterology Journal, 2021, 9, 343-353.	3.8	3
31	Association Between Polyp Detection Rate and Post-Colonoscopy Cancer Among Patients Undergoing Diagnostic Colonoscopy. Clinical Gastroenterology and Hepatology, 2021, 19, 202-204.	4.4	10
32	Pediatricâ€onset Inflammatory Bowel Disease Has Only a Modest Effect on Final Growth. Journal of Pediatric Gastroenterology and Nutrition, 2021, 73, 223-230.	1.8	2
33	Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice. Nature Genetics, 2021, 53, 500-510.	21.4	56
34	Dysbiosis in Metabolic Genes of the Gut Microbiomes of Patients with an Ileo-anal Pouch Resembles That Observed in Crohn's Disease. MSystems, 2021, 6, .	3.8	19
35	STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology, 2021, 160, 1570-1583.	1.3	1,054
36	Alteration in Urease-producing Bacteria in the Gut Microbiomes of Patients with Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2021, 15, 2066-2077.	1.3	10

#	Article	IF	CITATIONS
37	Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review. Expert Review of Gastroenterology and Hepatology, 2021, 15, 985-997.	3.0	35
38	Machine learning for selecting patients with Crohn's disease for abdominopelvic computed tomography in the emergency department. Digestive and Liver Disease, 2021, 53, 1559-1564.	0.9	4
39	Venous Thromboembolism Among Patients With Inflammatory Bowel Diseases is Not Related to Increased Thrombophilia. Journal of Clinical Gastroenterology, 2021, Publish Ahead of Print, .	2.2	1
40	Incidence of Colorectal Adenomas After Bariatric Surgery: Pre-operative Super Morbid Obesity Is Independently Associated with Increased Risk. Obesity Surgery, 2021, 31, 4220-4226.	2.1	4
41	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 1504-1505.	4.4	0
42	OMO-2â€Filgotinib efficacy in patients with ulcerative colitis by line of therapy: Phase 2b/3 selection results., 2021,,.		0
43	Epidemiology of Inflammatory Bowel Diseases in Israel: A Nationwide Epi-Israeli IBD Research Nucleus Study. Inflammatory Bowel Diseases, 2021, 27, 1784-1794.	1.9	26
44	Clinical approach to skin eruptions induced by anti-TNF agents among patients with inflammatory bowel diseases: insights from a multidisciplinary IBD-DERMA clinic. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110531.	3.2	2
45	The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational antiâ€ntegrin therapies. Medicinal Research Reviews, 2020, 40, 245-262.	10.5	60
46	Association between time to colonoscopy after a positive guaiac fecal test result and risk of colorectal cancer and advanced stage disease at diagnosis. International Journal of Cancer, 2020, 146, 1532-1540.	5.1	25
47	Predominantly Antibiotic-resistant Intestinal Microbiome Persists in Patients With Pouchitis Who Respond to Antibiotic Therapy. Gastroenterology, 2020, 158, 610-624.e13.	1.3	53
48	Clock Gene Disruption Is an Initial Manifestation of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 115-122.e1.	4.4	36
49	Predictors for poor outcome of hospitalized children with inflammatory bowel disease. European Journal of Pediatrics, 2020, 179, 157-164.	2.7	3
50	Comparative Effect of Proton-Pump Inhibitors on the Success of Triple and Quadruple Therapy for & lt; b> & lt; b> & lt; b> Helicobacter pylori< fi> & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; b> & lt; b> & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; b> & lt; b> & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; b> & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; b> & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; b> & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; b> & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; b> & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; b> & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; b> & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; footnote in the Success of Triple and Quadruple Therapy for & lt; footnote in the Success of Triple and Constant for the Success of Tripl	1.9	3
51	Neutrophil to lymphocyte ratio and risk of neoplastic progression in patients with Barrett's esophagus. Endoscopy, 2020, 53, 774-781.	1.8	8
52	Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force. Journal of Crohn's and Colitis, 2020, 14, S785-S790.	1.3	12
53	Reply. Gastroenterology, 2020, 159, 401-402.	1.3	0
54	Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. United European Gastroenterology Journal, 2020, 8, 1076-1085.	3.8	35

#	Article	IF	CITATIONS
55	Carriage of Colibactin-producing Bacteria and Colorectal Cancer Risk. Trends in Microbiology, 2020, 28, 874-876.	7.7	36
56	<p>Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1</p> . Clinical and Experimental Gastroenterology, 2020, Volume 13, 211-220.	2.3	4
57	Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study. United European Gastroenterology Journal, 2020, 8, 418-424.	3.8	24
58	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment® < sup > MMX® < /sup > ) for active, mildâ€toâ€moderate ulcerative colitis. United European Gastroenterology Journal, 2019, 7, 1171-1182.	3.8	9
59	Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 519-528.	8.1	63
60	Gut microbiota density influences host physiology and is shaped by host and microbial factors. ELife, $2019, 8, .$	6.0	118
61	Faecal Proteases from Pouchitis Patients Activate Protease Activating Receptor-2 to Disrupt the Epithelial Barrier. Journal of Crohn's and Colitis, 2019, 13, 1558-1568.	1.3	8
62	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. Digestive Diseases, 2019, 37, 266-283.	1.9	63
63	Clinical outcomes of endoscopic balloon dilatation of intestinal strictures in patients with Crohn's disease. Medicine (United States), 2019, 98, e16864.	1.0	17
64	Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes. American Journal of Gastroenterology, 2019, 114, 900-906.	0.4	24
65	Optimization of <sup>13</sup> Câ€urea breath test threshold levels for the detection of <i>Helicobacter pylori</i> infection in a national referral laboratory. Journal of Clinical Laboratory Analysis, 2019, 33, e22674.	2.1	14
66	Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel diseaseâ€"The Israeli real world experience. Digestive and Liver Disease, 2019, 51, 68-74.	0.9	24
67	Starch Consumption May Modify Antiglycan Antibodies and Fecal Fungal Composition in Patients With lleo-Anal Pouch. Inflammatory Bowel Diseases, 2019, 25, 742-749.	1.9	9
68	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. Journal of Crohn's and Colitis, 2019, 13, 539-540.	1.3	4
69	The Association of Inflammatory Bowel Diseases with Autoimmune Disorders: A Report from the epi-IIRN. Journal of Crohn's and Colitis, 2019, 13, 324-329.	1.3	32
70	Endoscopic findings and esophageal cancer incidence among Fanconi Anemia patients participating in an endoscopic surveillance program. Digestive and Liver Disease, 2019, 51, 242-246.	0.9	10
71	Cell-centred meta-analysis reveals baseline predictors of anti-TNF $\hat{l}$ ± non-response in biopsy and blood of patients with IBD. Gut, 2019, 68, 604-614.	12.1	153
72	Evaluating IBD-specific antiglycan antibodies in serum of patients with spondyloarthritis and rheumatoid arthritis: are they really specific?. Clinical and Experimental Rheumatology, 2019, 37, 32-36.	0.8	2

#	Article	IF	CITATIONS
73	Increase in Processing Factors Is Involved in Skewed MicroRNA Expression in Patients with Ulcerative Colitis Who Develop Small Intestine Inflammation after Pouch Surgery. Inflammatory Bowel Diseases, 2018, 24, 1045-1054.	1.9	7
74	Risk of Neoplastic Progression Among Patients with an Irregular Z Line on Long-Term Follow-Up. Digestive Diseases and Sciences, 2018, 63, 1513-1517.	2.3	12
75	Of mice and men: a novel dietary supplement for the treatment of ulcerative colitis. Therapeutic Advances in Gastroenterology, 2018, 11, 1756283X1774186.	3.2	16
76	Helicobacter pylori infection is positively associated with an increased BMI, irrespective of socioeconomic status and other confounders: a cohort study. European Journal of Gastroenterology and Hepatology, 2018, 30, 143-148.	1.6	36
77	Correlation between Quantitative <sup>13</sup> C-Urea Breath Test and <i>Helicobacter pylori</i> Treatment Success in a Population-Based Cohort. Gastroenterology Research and Practice, 2018, 2018, 1-6.	1.5	8
78	Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study. Clinical Epidemiology, 2018, Volume 10, 671-681.	3.0	48
79	Video capsule endoscopy is safe and effective in suspected small bowel bleeding among left ventricular assist device recipients. International Journal of Artificial Organs, 2018, 41, 833-837.	1.4	2
80	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach. Intestinal Research, 2018, 16, 522-528.	2.6	17
81	Improvement in the implementation of Helicobacter pylori management guidelines among primary care physicians following a targeted educational intervention. Annals of Gastroenterology, 2018, 32, 52-59.	0.6	13
82	Crohn's Disease Behavior and Location is Altered when Associated with Primary Sclerosing Cholangitis. Israel Medical Association Journal, 2018, 20, 25-29.	0.1	7
83	Restorative Proctocolectomy in Elderly IBD Patients: A Multicentre Comparative Study on Safety and Efficacy. Journal of Crohn's and Colitis, 2017, 11, jjw209.	1.3	20
84	Alterations of Enteric Microbiota in Patients with a Normal Ileal Pouch Are Predictive of Pouchitis. Journal of Crohn's and Colitis, 2017, 11, 314-320.	1.3	28
85	Prevention of Antidrug Antibody Formation to Infliximab inÂCrohn's Patients With Prior Failure of Thiopurines. Clinical Gastroenterology and Hepatology, 2017, 15, 69-75.	4.4	24
86	Comparing diagnostic yield of a novel pan-enteric video capsule endoscope with ileocolonoscopy in patients with active Crohn's disease: a feasibility study. Gastrointestinal Endoscopy, 2017, 85, 196-205.e1.	1.0	61
87	Magnetic resonance enterography or video capsule endoscopy & amp; ndash; what do Crohn& amp; rsquo; s disease patients prefer?. Patient Preference and Adherence, 2016, 10, 1043.	1.8	24
88	MicroRNAs Expression in the Ileal Pouch of Patients with Ulcerative Colitis Is Robustly Up-Regulated and Correlates with Disease Phenotypes. PLoS ONE, 2016, 11, e0159956.	2.5	19
89	Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial. Digestive Diseases and Sciences, 2016, 61, 3246-3254.	2.3	13
90	Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. BMJ Open Gastroenterology, 2016, 3, e000092.	2.7	7

#	Article	IF	Citations
91	Magnetic resonance enterography <i>versus</i> capsule endoscopy activity indices for quantification of small bowel inflammation in Crohn's disease. Therapeutic Advances in Gastroenterology, 2016, 9, 655-663.	3.2	41
92	Young GI Angle: What makes for a good mentor?. United European Gastroenterology Journal, 2016, 4, 320-320.	3.8	1
93	Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology, 2016, 150, 477-487.e9.	1.3	133
94	The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Re-classification of Disease in Patients with Known Crohn's Disease: A Prospective Israeli IBD Research Nucleus (IIRN) Study. Journal of Crohn's and Colitis, 2016, 10, 525-531.	1.3	64
95	Enterococcus faecalis Gelatinase Mediates Intestinal Permeability via Protease-Activated Receptor 2. Infection and Immunity, 2015, 83, 2762-2770.	2.2	62
96	Pouch Inflammation Is Associated With a Decrease in Specific Bacterial Taxa. Gastroenterology, 2015, 149, 718-727.	1.3	80
97	Infliximab-Related Infusion Reactions: Systematic Review. Journal of Crohn's and Colitis, 2015, 9, 806-815.	1.3	178
98	Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab. Clinical Gastroenterology and Hepatology, 2015, 13, 522-530.e2.	4.4	268
99	Significance of low level infliximab in the absence of anti-infliximab antibodies. World Journal of Gastroenterology, 2015, 21, 1907.	3.3	19
100	Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations: Table 1 Journal of Crohn's and Colitis, 2015, 9, 685-691.	1.3	71
101	Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents. Journal of Crohn's and Colitis, 2015, 9, 382-389.	1.3	7
102	ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation. Gut, 2015, 64, 367-372.	12.1	100
103	Gene expression alterations in ulcerative colitis patients after restorative proctocolectomy extend to the small bowel proximal to the pouch. Gut, 2015, 64, 756-764.	12.1	22
104	Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 2247-2259.	1.9	232
105	Sequential capsule endoscopy of the small bowel for follow-up of patients with known Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, 1616-1623.	1.3	61
106	Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet, The, 2014, 384, 309-318.	13.7	421
107	Results of the 4th Scientific Workshop of the ECCO (Group II): Markers of intestinal fibrosis in inflammatory bowel disease. Journal of Crohn's and Colitis, 2014, 8, 1166-1178.	1.3	65
108	Maternal inflammatory bowel disease has short and long-term effects on the health of their offspring: A multicenter study in Israel. Journal of Crohn's and Colitis, 2013, 7, 542-550.	1.3	35

#	Article	IF	CITATIONS
109	NOD2 and pouch complications in UC patients: old-world clinical dogmas give way to biological definitions. Gut, 2013, 62, 1390-1391.	12.1	1
110	MicroRNA-132 Modulates Cholinergic Signaling and Inflammation in Human Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2012, 18, S105-S106.	1.9	0
111	Normal Response to Vaccines in Inflammatory Bowel Disease Patients Treated with Thiopurines. Inflammatory Bowel Diseases, 2012, 18, 261-268.	1.9	73
112	CXCL12 Is a constitutive and inflammatory chemokine in the intestinal immune system. Inflammatory Bowel Diseases, 2010, 16, 583-592.	1.9	101
113	A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut, 2010, 59, 760-766.	12.1	49
114	New Serologic Markers for Inflammatory Bowel Disease Diagnosis. Digestive Diseases, 2010, 28, 418-423.	1.9	52
115	Disease Behavior in Adult Patients: Are There Predictors for Stricture or Fistula Formation?. Digestive Diseases, 2009, 27, 206-211.	1.9	20
116	Inflammatory bowel disease and colorectal cancer: What is new?. Current Colorectal Cancer Reports, 2009, 5, 35-39.	0.5	0
117	Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon- $\hat{l}^3$ . American Journal of Physiology - Renal Physiology, 2007, 292, G1630-G1640.	3.4	68
118	Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification. Expert Review of Gastroenterology and Hepatology, 2007, 1, 265-274.	3.0	10
119	Antibodies Against Laminaribioside and Chitobioside Are Novel Serologic Markers in Crohn's Disease. Gastroenterology, 2006, 131, 366-378.	1.3	219
120	Probiotics in inflammatory bowel disease: possible mechanisms of action. Current Opinion in Gastroenterology, 2005, 21, 426-30.	2.3	81
121	Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Digestive Diseases and Sciences, 2001, 46, 2239-2244.	2.3	50
122	Altered thyroid status modulates portal pressure in normal rats. Liver International, 1999, 19, 423-426.	3.9	2
123	Prediction of renal impairment in elderly patients with congestive heart failure treated with captopril. Cardiovascular Drugs and Therapy, 1996, 10, 75-79.	2.6	5
124	A novel endoscopic technique for closure of two gastro-gastric fistulas in a single session using an endoscopic helix tacking device. Endoscopy, 0, , .	1.8	0